Crescent Capital BDC Inc (CCAP) Stock Analysis
Verdict: WATCH (do not buy)
Heavy NAV discount (0.53x) offers cushion, but credit deterioration and recent analyst downgrades cap near-term recovery.
Investment score: 42/100
Analysis as of
Is Crescent Capital BDC Inc stock worth reviewing? AI model thesis
The model rates CCAP as a HOLD. While its current price of $10.03 represents an extraordinary discount to book value ($19.06/share) paired with a 9.86% yield, net income deterioration and ongoing analyst downgrades argue against aggressive capital commitment.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Crescent Capital BDC Inc opportunities and risks
What speaks for CCAP
- Severe Net Asset Value (NAV) Discount
What speaks against CCAP
- Portfolio Credit Deterioration and Non-Accruals
Frequently asked questions about Crescent Capital BDC Inc (CCAP)
Is CCAP stock a good investment?
The cached TradeMates AI model rates Crescent Capital BDC Inc as WATCH (do not buy) with an investment score of 42/100. The model rates CCAP as a HOLD. While its current price of $10.03 represents an extraordinary discount to book value ($19.06/share) paired with a 9.86% yield, net income deterioration and ongoing analyst downgrades argue against aggressive capital commitment. This is algorithmic model output, not personal investment advice.
Is CCAP stock a buy?
The TradeMates model verdict for CCAP is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.